Search research articles
Contact Us
Filters
Showing results (41-50 of 75) with videos related to
Page
of 8
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2008
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group
A Italiano, N Penel, Y-M Robin, et al.
Gynecologic Oncology
|
March 26, 2016
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072
C Benson, I Ray-Coquard, S Sleijfer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2013
Advanced chondrosarcomas: role of chemotherapy and survival
A Italiano, O Mir, A Cioffi, et al.
British Journal of Cancer
|
January 9, 2023
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
S Piperno-Neumann, M S Carlino, V Boni, et al.
ESMO Open
|
June 7, 2023
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
A Le Cesne, C Chevreau, C Perrin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2023
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
J M Piulats, C Watkins, M Costa-García, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 30, 2014
Response to chemotherapy is not related to chromosome instability in synovial sarcoma
C Chakiba, P Lagarde, D Pissaloux, et al.
ESMO Open
|
July 29, 2021
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
P Pautier, A Floquet, C Chevreau, et al.
Nature Medicine
|
May 26, 2022
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
A Italiano, A Bessede, M Pulido, et al.
Page
of 8
Search research articles
Search
Showing results (41-50 of 75) with videos related to
Sort By:
Page
of 8
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 18, 2008
Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group
A Italiano, N Penel, Y-M Robin, et al.
Gynecologic Oncology
|
March 26, 2016
Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072
C Benson, I Ray-Coquard, S Sleijfer, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 9, 2013
Advanced chondrosarcomas: role of chemotherapy and survival
A Italiano, O Mir, A Cioffi, et al.
British Journal of Cancer
|
January 9, 2023
A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma
S Piperno-Neumann, M S Carlino, V Boni, et al.
ESMO Open
|
June 7, 2023
Regorafenib in patients with relapsed advanced or metastatic chordoma: results of a non-comparative, randomised, double-blind, placebo-controlled, multicentre phase II study
A Le Cesne, C Chevreau, C Perrin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 4, 2023
Overall survival from tebentafusp versus nivolumab plus ipilimumab in first-line metastatic uveal melanoma: a propensity score-weighted analysis
J M Piulats, C Watkins, M Costa-García, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 14, 2019
A phase II of gemcitabine combined with pazopanib followed by pazopanib maintenance, as second-line treatment in patients with advanced leiomyosarcomas: A unicancer French Sarcoma Group study (LMS03 study)
P Pautier, N Penel, I Ray-Coquard, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
July 30, 2014
Response to chemotherapy is not related to chromosome instability in synovial sarcoma
C Chakiba, P Lagarde, D Pissaloux, et al.
ESMO Open
|
July 29, 2021
A single-arm multicentre phase II trial of doxorubicin in combination with trabectedin in the first-line treatment for leiomyosarcoma with long-term follow-up and impact of cytoreductive surgery
P Pautier, A Floquet, C Chevreau, et al.
Nature Medicine
|
May 26, 2022
Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort
A Italiano, A Bessede, M Pulido, et al.
Page
of 8